Lonza's Synaffix Partners with Sidewinder Therapeutics to Develop Next-Generation Bispecific ADCs for Solid Tumors
核心洞察
Synaffix (搜索), a Lonza company, has entered into a multi-target licensing agreement with Sidewinder Therapeutics (搜索) to develop first-in-class bispecific antibody-drug conjugates (搜索) for solid tumor treatment.
The collaboration combines Sidewinder's precision bispecific antibodies with enhanced tumor-cell specificity and internalization with Lonza's clinically validated ADC platform technologies.
Sidewinder gains access to Lonza's site-specific ADC technology platform including GlycoConnect (搜索)® antibody conjugation, HydraSpace (搜索)® polar spacer, and toxSYN (搜索)® linker payload technologies.
Synaffix (搜索) B.V., a Lonza company focused on commercializing clinical-stage platform technology for antibody-drug conjugates (搜索) (ADCs), has announced a multi-target licensing agreement with Sidewinder Therapeutics (搜索) to develop first-in-class bispecific ADC therapeutics targeting solid tumor indications. The collaboration brings together two cutting-edge platforms designed to enhance tumor-cell internalization while minimizing impact on healthy tissue.
Technology Platform Integration
Through the agreement, Sidewinder gains access to Lonza's clinically validated, site-specific ADC technology platform, which includes three key components: GlycoConnect (搜索)® antibody conjugation technology, HydraSpace (搜索)® polar spacer technology, and a toxSYN (搜索)® linker payload. This comprehensive platform enables the development of ADC products with what the companies describe as a best-in-class therapeutic index.
The Synaffix (搜索) platform is designed to enable a rapid timeline to clinic due to its established supply chain of technology components. Synaffix holds granted patents to its technology and operates under a business model of target-specific technology out-licensing.
Strategic Partnership Structure
Under the terms of the agreement, Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. The companies have divided responsibilities, with Lonza handling manufacturing of components related to its proprietary technologies, while Sidewinder takes responsibility for research, development, manufacturing, and commercialization of the ADCs.
Peter van de Sande, Head of Synaffix (搜索) at Lonza, stated: "This collaboration brings together two cutting-edge platforms to enhance the therapeutic index of bispecific ADCs (搜索) by minimizing impact on healthy tissue. We are confident that our technologies will help Sidewinder's pipeline reach its full potential in maximizing tumor targeting, hence delivering new life-saving therapies for the benefit of patients with cancer (搜索)."
Bispecific ADC Innovation
Sidewinder Therapeutics (搜索) specializes in developing precision ADC therapeutics with a pipeline of bispecific antibodies designed to enhance tumor-cell specificity and internalization. The company's approach targets tumor-specific receptor complexes (搜索), which when combined with Synaffix (搜索)'s clinically validated site-specific linker-payload platform, creates what the companies describe as an ideal synergy.
Eric Murphy, PhD, Co-Founder and Chief Executive Officer of Sidewinder Therapeutics (搜索), commented: "The ADC field has reached an exciting moment fueled by multiple technology breakthroughs that enable the next generation of bispecific ADC innovation. Sidewinder's bispecific antibody approach targeting tumor-specific receptor complexes (搜索) combined with Synaffix (搜索)'s clinically validated site-specific linker-payload platform creates an ideal synergy with the potential to greatly impact patient benefit."
Clinical Timeline and Company Background
Sidewinder expects to initiate a clinical trial for a first-in-class bispecific ADC in 2026. The company was founded in 2023 with Series A investment from OrbiMed (搜索) and is headquartered in San Diego, California.
Synaffix (搜索) was fully acquired by Lonza in June 2023. Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), operates across five continents with more than 19,000 employees. The company generated sales of CHF 3.6 billion with a CORE EBITDA of CHF 1.1 billion in Half-Year 2025.
The collaboration represents an effort to reshape the cancer (搜索) treatment landscape by improving tolerability for bispecific ADCs (搜索) while maintaining enhanced tumor targeting capabilities. The partnership leverages Sidewinder's precision bispecific antibody technology with Lonza's established ADC platform to develop what the companies anticipate will be first-in-class therapeutic options for solid tumor patients.